|
|
Downstream Product-Based Payments Overcome an R&D Budget Gap
Situation
A global pharmaceutical company had a promising new formulation of a marketed product in early Phase III trials, but R&D budget pressures were likely to result in delays getting the product to market.
Solution
NovaQuest is funding $200 million in development expenses related to the Phase III candidate. In return, it will receive a variety of product-based returns.
Value Added
The deal resolves development budgetary gaps and is at a magnitude sufficient to jump start the product's development.
|